Drug Information

Drug General Information
Drug ID
D04MBS
Former ID
DIB005355
Drug Name
BMS-182657
Indication Cardiovascular disorder [ICD10:I00-I99] Terminated [533583]
Company
Bristol-Myers Squibb Co
Canonical SMILES
N1(C(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)S)CCc2c1cccc2)CC(=<br />O)O
CAS Number
CAS 160135-56-8
Target and Pathway
Target(s) Neutral endopeptidase Target Info Modulator [533583]
Angiotensin-converting enzyme Target Info Modulator [533583]
KEGG Pathway Renin-angiotensin system
Hematopoietic cell lineage
Protein digestion and absorption
Alzheimer's diseasehsa04614:Renin-angiotensin system
Chagas disease (American trypanosomiasis)
Hypertrophic cardiomyopathy (HCM)
NetPath Pathway EGFR1 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
PathWhiz Pathway Angiotensin Metabolism
Reactome Metabolism of Angiotensinogen to AngiotensinsR-HSA-2022377:Metabolism of Angiotensinogen to Angiotensins
WikiPathways Metabolism of Angiotensinogen to Angiotensins
Primary Focal Segmental Glomerulosclerosis FSGS
Alzheimers DiseaseWP554:ACE Inhibitor Pathway
References
Ref 533583Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52.
Ref 533583Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.